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Cell-derived extracellular vesicles can be used
as a biomarker reservoir for glioblastoma
tumor subtyping
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Graeme Benstead-Hume 3, Frances M.G. Pearl 3, Giles Critchley4, Justin Stebbing5 & Georgios Giamas1
Glioblastoma (GBM) is one of the most aggressive solid tumors for which treatment options
and biomarkers are limited. Small extracellular vesicles (sEVs) produced by both GBM and
stromal cells are central in the inter-cellular communication that is taking place in the tumor
bulk. As tumor sEVs are accessible in bioﬂuids, recent reports have suggested that sEVs
contain valuable biomarkers for GBM patient diagnosis and follow-up. The aim of the current
study was to describe the protein content of sEVs produced by different GBM cell lines and
patient-derived stem cells. Our results reveal that the content of the sEVs mirrors the phe-
notypic signature of the respective GBM cells, leading to the description of potential infor-
mative sEV-associated biomarkers for GBM subtyping, such as CD44. Overall, these data
could assist future GBM in vitro studies and provide insights for the development of new
diagnostic and therapeutic methods as well as personalized treatment strategies.
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G lioblastoma multiforme (GBM) is amongst the mostaggressive types of brain tumors for which current treat-ments are of limited beneﬁt1. Verhaak et al. has previously
described different clinical genetic GBM subtypes (proneural,
neural, mesenchymal, and classical) based on the gene expression
of different markers, such as platelet-derived growth factor-
receptor alpha (PDGF-Rα), neuroﬁlament light (NEFL), CD44,
and epidermal growth factor-receptor (EGF-R), respectively2.
This sub-classiﬁcation might have diagnostic and prognostic
applications as, for example, the mesenchymal subtype is
acknowledged as the most aggressive one3,4. Nevertheless, all
these subtypes can co-exist within the same tumor, making
patients’ sub-classiﬁcation challenging5. In addition, according to
recent reports, the neural subtype may simply represent normal
brain contamination6.
During GBM growth, the close crosstalk between the different
components of the integrated GBM microenvironment, including
the hyaluronic acid (HA)-rich extracellular matrix and stromal
cells, such as endothelial cells or astrocytes, can support tumor
invasiveness and resistance to therapy7. In addition, an important
role in tumor recurrence and resistance to treatment is attributed
to GBM stem cells present in the tumor bulk as they are less
affected by radio-therapy and chemo-therapy8–10. Such resistance
is further supported by GBM stem cells capabilities to generate
different GBM cell sub-populations of various molecular
signatures11,12. Intra-tumoral heterogeneity is therefore a central
feature of GBM tumors, although it has not been fully described
to date13,14. Nevertheless, a better understanding of GBM het-
erogeneous sub-populations/molecular signatures would be of
great help for future in-depth studies and, eventually, novel
therapeutic strategies.
Extracellular vesicles (EVs) represent one of the plausible ways
through which tumor cells, including cancer stem cells, self-
regulate and communicate with their stromal counterparts and
hence maintain such high intra-tumoral heterogeneity15. EVs are
membrane-enclosed vesicles that can carry proteins, lipids,
metabolites, and nucleic acids from one cell to another, for short
or long distances16,17. In GBM, EVs have been described to be
involved in tumor invasion, neo-angiogenesis, modulation of the
immune response and resistance to treatments such as temozo-
lomide18–20. Recent reports have focused on the role of small EVs
(sEVs, <200 nm diameter) in cancer progression, as opposed to
medium/large EVs (m/lEVs, >200 nm)15,21. We have recently
reported that shedding of bevacizumab, an antibody neutralizing
VEGF-A, at the surface of GBM cell-derived sEVs might be
involved in the tumor resistance to anti-angiogenic therapies22.
Furthermore, recent reports suggested that GBM cells of distinct
subtypes/molecular signatures accordingly produce EVs with dif-
ferent contents3,23,24. Indeed, Spinelli et al. showed that proneural
and mesenchymal GBM stem cells produce different EVs in terms
of proteomic content and pro-angiogenic effects23. By describing
the proteomic cargo of GBM cell line-derived EVs,
Mallawaaratchy et al. identiﬁed EV biomarkers that are poten-
tially associated with higher GBM invasiveness, such as Annexin
A1 and Integrin ß1. Interestingly, through a gene expression
analysis of GBM specimens, authors reported that Annexin A1
expression is higher in the mesenchymal and classical subtypes,
suggesting a survival/subtype prediction potential for EV-
associated Annexin A13. Similarly, blood-derived and cere-
brospinal ﬂuid (CSF)-derived EV cargos have been recently
proposed as good biomarker candidates for diagnosing GBM and
describing speciﬁc subtypes/molecular signatures, and also for
assessing tumor resistance to existing therapies18,25,26. Indeed, the
presence of EVs in bioﬂuids along with their capability to cross
the blood brain barrier, makes them very valuable carriers of
potential GBM biomarkers, while current methods for the
purposes of diagnosis/prognosis are still painful and
invasive15,27,28. Recently, Osti et al. reported higher levels of EVs
in GBM patients compared to healthy controls, suggesting a new
potential method to help GBM diagnosis24. Nevertheless, there is
still a great need for identifying precise EV-associated biomarkers
that could help determine speciﬁc GBM tumor subtype/molecular
signatures in patients. In addition, as the EV ﬁeld is constantly
evolving and relies a lot on fast growing and highly EV-producing
tumor cell lines, an extended description of available models for
EV-related GBM research would be of great value.
For all these reasons, our aim was to describe the proteomic
content of sEVs derived from GBM cells with various molecular
signatures. We ﬁrst grouped GBM cell lines and patient-derived
stem cells according to the expression of speciﬁc key markers and
their in vitro invasiveness potential. Interestingly, we were able to
associate some of the cell sub-groups that we identiﬁed to GBM
subtypes/molecular signatures that have already been described2.
Ultimately, we observed that description of the proteomic content
of the GBM cell-derived sEVs mirrored our original cell grouping.
Consequently, this extensive study led to the identiﬁcation of new
potential sEV-associated protein biomarkers that can be used as
indicators of GBM aggressiveness and assist in GBM subtype
classiﬁcation.
Results
In vitro invasion capabilities of astrocytes and GBM cells.
Invasion assays in 3D HA-hydrogels were undertaken to deter-
mine the colony forming abilities of astrocytes and GBM cells
(Fig. 1a and Supplementary Data 1). LN18, LN229, and U87 cells
formed the highest number of colonies with an average of 52, 48,
and 64 colonies per well, respectively (p= 0.0003, p= 0.0008, and
p= 0.0001 compared to astrocytes, respectively), while U118,
U138, and GS090 cells had 31, 32, 19, and 31 colonies, respec-
tively (p= 0.0407, p= 0.0283, and p= 0.0417 compared to
astrocytes, respectively). T98, G166 cells, and astrocytes’ number
of colonies were signiﬁcantly lower (13 and 2 per well, respec-
tively, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ordinary
one-way ANOVA) (Fig. 1a and Supplementary Data 1). To fur-
ther describe the GBM cells’ behavior when growing in the HA
hydrogels, we then performed a cell viability assay (Fig. 1b and
Supplementary Data 1). The relative viability, expressed here in
Relative Light Units (RLU), was 4.2, 3.5, 4.95, 2.4, and 4.2 fold
higher in LN18, LN229, U87, U138, and GS090 cells, respectively,
when compared to astrocytes (p= 0.0033, p= 0.0251, p= 0.0004,
p= 0.0323, and p= 0.0034 compared to astrocytes, respectively).
The viability of T98, U118, and G166 cells was not signiﬁcantly
different to the astrocytes’ (*p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001, ordinary one-way ANOVA) (Fig. 1b and Sup-
plementary Data 1).
Further assays were implemented to complete our under-
standing of the migration, proliferation, and invasion capabilities
of the studied cells. As presented in Fig. 1c, U87 cells were able to
invade through a basement membrane matrix-coated insert more
than any of the other cell lines. Indeed, when compared to the
control (no FCS), U87 cells migrated 66% more into the matrix in
the presence of FCS in the lower chamber (Fig. 1c and
Supplementary Data 1). In addition, as shown in Supplementary
Fig. 1A, AS, U118 and U138 showed the highest migration
potential with 77%, 76%, and 72% wound healing, while LN229
and U87 cells had a 43% and 53% closure, respectively
(Supplementary Data 2). LN18 and T98 cells’ wound healing
abilities were signiﬁcantly lower than the one observed in AS
(40%, p= 0.0441 and 7%, p= 0.0003 respectively, *p < 0.05, **p <
0.01, ***p < 0.001, ****p < 0.0001, ordinary one-way ANOVA).
Furthermore, U87 cells presented the shortest population
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doubling time (25.5 h, p= 0.0019 compared to AS), followed by
LN229, LN18, and T98 (26.6 h, p= 0.0023, 28.2 h, p= 0.0029 and
30.1 h, p= 0.0039 respectively, *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001, ordinary one-way ANOVA) (Supplementary
Fig. 1B and Supplementary Data 2).
Taken together, our results conﬁrm that AS are quite motile in
2D albeit their low invasiveness potential in 3D. T98 cells had
equally limited migration and invasion capabilities. Despite their
restricted in vitro motility, showing both low wound healing and
basement membrane invasion, LN18 and LN229 GBM cells were
signiﬁcantly more invasive in HA hydrogels compared to AS
(second and third most invasive, respectively) and had short
population doubling times. U87, U118, and U138 cells presented
higher migration abilities compared to the other GBM cells and
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signiﬁcantly higher invasiveness in HA hydrogels vs. the AS.
Among these, only U87 cells displayed the highest basement
membrane matrix invasion along with the shortest population
doubling time. Amongst the stem cells, only GS090 showed a
signiﬁcantly higher invasive potential, in the HA hydrogels, vs.
the AS. Overall, from all the GBM cells that we analyzed, U87
cells had the highest invasion capabilities.
Expression of signature markers in GBM cells and astrocytes.
Using the Verhaak et al. classiﬁcation, we then assessed in our cell
line panel the expression of different markers related to the (i)
‘classical’ (EGF-R), (ii) ‘mesenchymal’ (Neuroﬁbromatosis type 1
(NF1), CD44), (iii) ‘proneural’ (PDGF-Rα, Oligodendrocyte
transcription factor 2 (OLIG2), SOX2), or (iv) ‘neuronal’ (NEFL)
signatures2. In addition, the expression levels of PTEN, vimentin,
and vascular endothelial growth factor-a (VEGFA) have been
determined with the aim of obtaining further information
regarding the tumor cells’ aggressiveness.
Gene expression analysis showed signiﬁcantly lower levels of
EGF-R in LN229 and GS090 cells compared to AS (95% lower, p
= 0.005 and p= 0.0041 respectively), while NF1 levels were
signiﬁcantly <50% in all GBM cells when compared to AS, except
from G166 cells (+47% compared to AS). OLIG-2 appeared to be
expressed ~30× more in LN229 (p= 0.0072) and GS090 (p=
0.0023) cells than in AS while its levels were low in the other
GBM cells. PDGF-Rα expression was observed at its highest in
LN18 (p= 0.0182) and U138 (p= 0.0337) cells (10×-fold and 9×-
fold higher compared to AS, respectively). PTEN was present at
similar extents in most of the cells, including the AS, except from
the U118 (p= 0.0292), U138 (p= 0.0323), and GS090 (p=
0.0368) cells where it was hardly detectable. Finally, regarding
VEGF-A, only U87 and U118 cells showed signiﬁcantly higher
levels (>5×-fold higher, p= 0.0074 and p= 0.0009, respectively)
vs. the AS (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001,
ordinary one-way ANOVA) (Fig. 1d and Supplementary Data 3).
Most of these discrepancies were recapitulated by western
blotting (Fig. 1e, f, Supplementary Figs. 2 and 3). PTEN was
mainly detected in T98 and LN229 cells, while CD44 was highly
expressed in LN18, T98, U87, and G166 cells. Similarly, c-Met
was over-expressed in U87, T98, LN18, and G166 cells. Regarding
NEFL, its expression could only be observed in AS as well as in
U118 and U138 cells (Fig. 1e, f, Supplementary Figs. 2 and 3).
Finally, ELISA assays demonstrated that VEGF-A cytokine
secretion is signiﬁcantly higher in U87 (p= 0.0003), U118 (p=
0.0011), U138 (p= 0.0359), and G166 (p= 0.0005) cells than in
AS (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ordinary
one-way ANOVA) (Fig. 1g and Supplementary Data 4).
In summary, our genomic/proteomics analyses revealed
distinctive expression of GBM subtype markers within the panel
of GBM and stem cells that were tested.
Clustering of GBM cells into different signatures. The inva-
siveness and gene/protein markers’ expression data presented in
Fig. 1 were put together and compared through clustering ana-
lysis resulting in the identiﬁcation of seven distinctive signatures
using non-negative matrix factorization (Fig. 2a and Supple-
mentary Data 5). Then, based on these expression signatures,
GBM and stem cells have been compared and clustered together
according to their similarities. As shown in Fig. 2b, U118 and
U138 were grouped together in a common sub-cluster while U87,
T98, G166, GS090, LN229, and LN18 failed to cluster with any
other studied GBM cell line (Supplementary Data 5).
Our analysis revealed that LN18, U87, U118, G166, and GS090
GBM cells express distinct parameter/marker signatures, suggest-
ing that they could represent distinct GBM signatures. Hence, a
separate four signature clustering of the parameters shown in
Fig. 1 has been generated to further describe the LN18, U87,
U118, G166, and GS090 cell lines (Fig. 2c and Supplementary
Data 5). Signature 1 was mostly characterized by high VEGF
expression, high CD44 protein expression, high cMET protein
expression, low PTEN protein expression, and high invasiveness
potential (high number of ‘colonies in HA hydrogels’, ‘Viability in
HA hydrogels’ and ‘Basement membrane invasion’) (Fig. 2c and
Supplementary Data 5). Signature 2 was mostly characterized by
high PDGF-R, OLIG2, and SOX2 gene expression, as described in
GS090 GBM cells (Fig. 2d and Supplementary Data 5). Inversely,
signature 3 showed high vimentin protein expression associated
with high CD44 protein expression, high NF1 gene expression
and high EGF-R gene expression. As seen in Fig. 2d, signature 3
was mainly observed in G166 GBM cells. Signature 4, which was
observed in U118 GBM cells, was deﬁned by high VEGF-A gene
expression production as well as high vimentin protein expres-
sion (Fig. 2d and Supplementary Data 5). Finally, as shown in
Fig. 2d, a strong association of signature 1 with LN18 and U87
GBM cells could be observed. In addition, cosine similarity assay
conﬁrmed the high similarity between LN18 and U87 (Supple-
mentary Fig. 4 and Supplementary Data 6).
Analysis of GBM cell-derived sEVs size and concentration.
Based on our aforementioned clustering results, we decided to
focus on these ﬁve distinct GBM cells, namely LN18, U87, U118,
G166, and GS090. Description of their respective sEV production
and proteomic cargo was undertaken in an attempt to identify
GBM signature markers in their EVs.
Fig. 1 Astrocytes (AS), GBM cell lines, and GBM patient-derived stem cells present different in vitro invasion capabilities and speciﬁc subtype marker
expression. a AS and GBM cells invasiveness and colony formation abilities using a hyaluronic acid (HA)-based hydrogel assay. Cells were incubated within
a HA hydrogel for 7 days. Colony counting was then performed. Scale bar= 400 µm. b AS and GBM cell viability in a HA hydrogel-based assay using the
CellTiter-Glo® Luminescent Cell Viability Assay. c Invasion abilities of AS and GBM cells through an extracellular matrix-coated membrane. Cells were
seeded in the top chamber and were allowed to invade the matrix for 24 h in presence or absence of FCS in the bottom chamber. Cells that have passed
through the matrix were then detached, lysed, and labeled with CyQuant GR Dye. Fluorescence was then read (480/520 nm ﬁlter set). Data obtained in
presence of FCS was normalized to data obtained without FCS. Representative images are shown. d qRT-PCR analysis of GBM subtype and aggressiveness
marker expression in astrocytes, six different GBM cell lines and two different GBM patient-derived stem cells. GAPDH was used as an internal control.
Data are shown as normalized to AS data. Heat-map representative of the qRT-PCR data where the data is normalized to the highest level of gene
expression. e Western blotting analysis of GBM subtype and aggressiveness marker expression in AS and six different GBM cell lines. β-actin was used as
an internal control. fWestern blotting analysis of GBM subtype and aggressiveness marker expression in astrocytes and two different GBM patient-derived
stem cells. β-actin was used as an internal control. g ELISA analysis of VEGF-A secretion by AS, six different GBM cell lines and two different GBM patient-
derived stem cells. Representative images are shown. The mean ± SEM of n= 3 independent experiments is shown. *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001 (ordinary one-way ANOVA)
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Size distribution and concentration of sEVs derived from the
selected GBM cells were initially determined by NTA. As shown
in Fig. 3a, EV concentration (particles /mL/cell) at the size mode
was: 60.3 particles/mL/cell for LN18, 59.9 particles /mL/cell for
U87, 69 particles /mL/cell for U118, 259.2 particles /mL/cell for
G166 and 97.2 particles /mL/cell for GS090. The average EV size
modes were: 86.6 nm for LN18, 86.3 nm for U87, 94.6 nm for
U118, 80.48 nm for G166 and 81.5 nm for GS090 (Fig. 3b and
Supplementary Data 5). Total sEV concentration was 4460
particles /mL/cell for LN18, 3790 particles /mL/cell for U87, 8650
particles /mL/cell for U118, 14,000 particles /mL/cell for G166
and 4520 particles /mL/cell for GS090 GBM cells. As shown in
Fig. 3c, concentration of sEVs produced by G166 GBM stem
cells was signiﬁcantly higher than the concentration of sEVs
produced by either LN18 (p= 0.0009), U87 (p= 0.0004) or
GS090 (p= 0.0025) GBM cells (*p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001, ordinary one-way ANOVA) (Fig. 3c and Supple-
mentary Data 7).
Furthermore, coupled to the NTA results, the TEM pictures in
Fig. 3d showing vesicles in the well-described size range of
50–150 nm further conﬁrmed the EV isolation from the different
GBM cell culture CM17.
Mass spectrometry (MS) analysis of GBM cell-derived sEVs.
Using MS, the proteomic content of the sEVs derived from
LN18, U87, U118, G166, and GS090 has been deciphered (Fig. 4
and Supplementary Data 8). Gene enrichment analysis for
‘Cellular component’ conﬁrmed the ‘exosomes’ origin of most
of the identiﬁed proteins (>70% of genes in all GBM cell-
derived sEVs) (Fig. 4a). Venn diagrams (Fig. 4b, c) revealed the
maximum protein expression overlap between U118 and U87
GBM cell-derived sEV content (46.7%). Proteomic content of
sEVs derived from LN18 GBM cells mostly overlapped with the
content of U118 (42.2%) and U87 (39.0%) GBM cell-derived
sEVs. Proteomic content of sEVs derived from GS090 showed
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low similarity (<25%) to any other GBM cell-derived sEV
proteomic content, with the highest overlap observed with the
G166 GBM cell-derived sEV content (23.5%). Altogether, as
shown in Fig. 4c, grouping of GBM cell-derived sEV proteomic
content distinctly clustered LN18, U87, and U118 together as
opposed to G166 and GS090 GBM cells (Fig. 4 and Supple-
mentary Data 8).
Similarly, gene enrichment analysis for ‘Biological pathways’
and ‘Biological processes’ showed enrichment of the ‘Metabolism’
pathway and Metabolism’ and ‘Energy pathways’ processes in the
proteomic content of sEVs derived from G166 and GS090 GBM
cells, as opposed to the other tumor cell-derived sEVs (Fig. 4d, e).
Inversely, our analysis revealed enrichment of pathways such as
‘Beta1 integrin cell surface interactions’, ‘Proteoglycan syndecan-
mediated signaling events’ or ‘VEGF and VEGFR signaling
network’ in the proteomes of sEVs derived from LN18, U87, and
U118 GBM cells. Processes such as ‘Signal transduction’ and ‘Cell
communication’ were also predominant (>25%) in sEVs derived
from those GBM cells (Fig. 4d, e, Supplementary Fig. 5 and
Supplementary Data 8).
A further detailed analysis of the proteomes of the studied
GBM cell-derived sEVs showed a shared expression of known EV
markers or proteins commonly present in EVs, such as Annexin
A2 (ANXA2), CD63, ﬁbronectin (FN1), GAPDH, or tubulin
(TUBB). Furthermore, other EV markers such as CD82, CD81,
CD9, TSG101, or ADAM10 could be detected in sEVs derived
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from LN18, U87, and U118. CD82 was also observed in G166
GBM cell-derived sEVs (Fig. 4 and Supplementary Data 8).
Notably, CD44, a now well-described marker of aggressive
mesenchymal GBM, was identiﬁed in sEVs derived from LN18,
U87, U118, and G166 GBM cells29 (Supplementary Fig. 6 and
Supplementary Data 9).
As we initially grouped LN18 and U87 GBM cells together
(signature 1) showing the highest levels of in vitro invasiveness
(Fig. 2), we thoroughly looked for potential relevant markers of
GBM aggressiveness among the protein hits exclusively present in
both sEV fractions derived from these cell lines. By doing so, we
identiﬁed WNT5a, TGFBI, and SERPINE1, all recently associated
with the GBM mesenchymal subtype and tumor invasion30–32, as
well as GDF-15, also known to be linked to GBM progression
and poor prognosis33,34. TCGA data conﬁrmed the signiﬁcant
association of a high expression of SERPINE1 and TGFBI with
mesenchymal subtype in GBM patients (Supplementary Fig. 6
and Supplementary Data 9).
Finally, we further evaluated the distribution of speciﬁc
markers in sEVs produced by the different GBM cells, including
ﬁbronectin, CD63, HSP70, Annexin A2, CD9 CD81, as well as
CD44 which has been recently observed at the surface of EVs
from different sources, such as ovarian and breast cancer cells but
also mesenchymal stem cells, whilst being associated with GBM
progression and aggressiveness23,29,35–37.
Overall, Fig. 4f show that sEVs derived from signature
1-associated LN18 and U87 GBM cells display similar levels of
CD63, HSP70, and Annexin A2 while sharing the highest
expression of CD63 and CD9 with signature 4 (U118 cells), as
compared to sEVs derived from G166 and GS090 stem cells. Both
sEV fractions from G166 and GS090 cells had low levels of CD63
and CD9 expression. Highest expression of FBN was observed in
U87 and G166 GBM cell-derived sEVs. Furthermore, CD44 was
clearly detected only in LN18, U87, and G166 GBM cell-derived
sEVs (Fig. 4f and Supplementary Fig. 7).
Discussion
Distinct molecular subtypes have been deﬁned in order to make
GBM diagnosis more precise, with direct links to tumor aggres-
siveness and patients overall survival2. Nevertheless, clinical
application of such subtyping is still quite limited, due to a lack of
reliable and accessible biomarkers. For these reasons, the present
study aimed to describe markers for speciﬁc GBM signatures in
sEVs derived from tumor cells, according to their in vitro inva-
sion potential. We believe that such biomarkers should be
detectable in sEVs derived from patients’ bioﬂuids (i.e. blood or
CSF), thus helping diagnosis and development of future perso-
nalized therapies3.
Indeed, by correlation clustering of our phenotypic and
molecular results, we could deﬁne distinct signatures to describe
the GBM cells that were employed in this study. Interestingly, in
accordance with the widely used Verhaak classiﬁcation and other
recent reports, signatures 1 and 2 presented characteristics spe-
ciﬁcally associated with the mesenchymal and proneural subtype,
respectively. Indeed, as often reported for the mesenchymal GBM
subtype, signature 1 was mostly characterized by high CD44 and
cMET expression, as well as high cell invasiveness. Similarly,
proneural markers such as high PDGF-R and OLIG2 expression
were the main parameters linked to signature 2. Signature 3 and 4
could not be clearly linked to any of the described GBM subtypes
even though signature 3 presented the highest EGF-R gene
expression, a marker for the classical GBM subtype.
Interestingly, the cell clustering was mirrored in the proteomic
content of sEVs derived from these GBM cells. Indeed, according
to our MS data and gene-enrichment analysis, there was a clear
separation between LN18, U87, and U118 on one side and G166
and GS090 on the other. Such discrepancy was further supported
by the identiﬁcation of biological pathways and processes in the
sEV proteomes. According to our analysis, the content of EVs
derived from U87, U118, and LN18 appeared similar while being
enriched in signaling pathways, such as ‘Integrin family cell
surface interaction’ or ‘VEGF and VEGFR network’, known to be
directly linked to GBM progression. On the other hand, the EV
proteomic signature of G166 and GS090 cells was mostly related
to ‘normal conditions’ machinery/metabolism pathways, e.g.
‘Energy pathways’ or ‘Metabolism’38,39. Such discrepancies in the
EV cargo between GBM cell lines and GBM stem cells may be due
to the remarkable metabolic ﬂexibility of cancer stem cells, as
opposed to normal/proliferative cancer cells40,41, which can have
a direct impact on the EV cargo of GBM stem cells15.
Moreover, differences could also be observed when looking
closely at the expression levels of sEV speciﬁc markers, such as
CD63, HSP70, Annexin A2, and CD9. sEVs derived from LN18,
U87, and U118 GBM cells had similar expression patterns when
compared to GBM stem cell-derived sEVs. Furthermore, sEVs
from signature 2 (GS090 stem cells) only showed clear expression
of CD9 and ﬁbronectin, as recently reported in a similar way for
‘proneural’ GBM cell-derived EVs by Spinelli et al.23. In accor-
dance with our present data, authors indeed showed that
the GBM stem cell subtype affected EV molecular characteristics
as sEVs produced by proneural GBM stem cells had very low
levels of CD9, CD63, and CD81 expression compared to sEVs
derived from mesenchymal GBM stem cell cultures23,42. Finally,
the similarities spotted between G166 and LN18 cells (signature
1) and between U118 and U87 cells (signature 4) were partially
recapitulated in our proteomic analysis of the EVs-content. Such
nuances could be related to the differences in the in vitro
migration/invasion capabilities we observed between LN18 and
U87 GBM cells. As both cell lines show mesenchymal features
(signature 1), we consider LN18 cells to be in an intermediate
mesenchymal state, as opposed to the fully invasive mesenchymal
U87 cells. Indeed, one could argue that such observation appears
similar to a ‘go-or-grow’ model where LN18 cells would rather
‘grow’ into a ‘tumor friendly’ microenvironment characterized by
HA abundance than ‘go’ and migrate through the basement
membrane and further invade surrounding tissue layers43,44.
Taken together, based on the current MS data and speciﬁc sEV
markers expression, LN18, U87, and U118 appeared to cluster
together, as similarly observed in our four-signature clustering
that grouped signature 1 (LN18 and U87) along with signature 4
(U118), while our 7-signature clustering also initially grouped
LN18 and U118 GBM cells together. Yet, LN18 and U87 on one
hand and U118 on the other hand clearly differ in terms of cMET
and CD44 expression, as well asin their invasiveness in the HA
hydrogels45. As a matter of fact, the low expression of CD44 in
sEVs derived from U118 GBM cells seems indicative of such
difference with LN18 and U87 cells. Our data suggest that sEV-
associated CD44 expression could be correlated with GBM cell
invasiveness. Yet, as high CD44 has been detected in sEVs derived
from low invasive G166 cells, and in accordance with the rest of
our results, we thus think that distinct GBM signatures/subtypes
might be differently associated with exclusive expression levels of
a few selected EV-associated markers. Accordingly, recent reports
suggested that proﬁling the expression of surface EV proteins
could provide cancer diagnostic signatures from bioﬂuids36.
Along with CD44, our results suggest TGFBI and SERPINE1
(PAI-1) as potential sEV-associated biomarkers for the aggressive
mesenchymal subtype31,32. We especially focused on CD44 as it
has often been associated with the mesenchymal phenotype and
cell invasion in GBM29,37,45. Accordingly, EV-associated CD44
has been linked to tumor progression and resistance to treatment
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in breast cancer and myeloma, respectively37,46,47. Furthermore,
we suggest that such biomarkers could help the follow-up of
GBM tumors and the monitoring of recurrence/treatment resis-
tance24. In the same way, an increase of the expression of pro-
teins, such as ECM1, CD9, and CD44 has been reported in
EVs derived from squamous cell carcinoma cells upon
mesenchymal transformation48,49. Altogether, both our data and
recent publications suggest that changes in the EV-speciﬁc mar-
ker expression patterns could help identify highly invasive/
aggressive tumors.
A few studies have already reported EV-associated markers
that could be used for discriminating GBM from normal and
stromal CNS cells, such as annexins and integrins3,42. Combined
with deciphering the expression of speciﬁc EV markers and EV-
associated GBM subtype markers, such integrated approaches
should provide an accurate diagnosis with potential subtype
characterization. Nevertheless, both cellular and molecular het-
erogeneity has been repeatedly reported in GBM tumors2. For
these reasons, characterizing a GBM tumor subtype based on the
respective EV proteomic content appears quite challenging, as
markers from various subtypes might be present in patients’
samples5. Nevertheless, precise quantiﬁcation of the EV-
associated markers should give further information regarding
the tumor main molecular signature and, consequently, asso-
ciated prognosis.
We believe that this study supports the clinical potential of the
content of EVs derived from different GBM subtypes26.
According to our data, EVs may contain reliable protein markers,
in particular for the aggressive mesenchymal GBM subtype.
Interestingly, although all the different GBM subtypes can be
present in the same tumor, it has been suggested that the
mesenchymal subtype takes over upon recurrence50. Hence,
deciphering how speciﬁc GBM subtyping inﬂuences the EV cargo
may help us understand how GBM can progress and recur. In the
same way, patient follow-up could also beneﬁt from such work. A
limitation of the present study is the use of immortalized tumor
cell lines for studying GBM subtypes, despite the concomitant use
of two populations of GBM patient-derived stem cells2. Never-
theless, we believe that our present report can be of great help for
future functional in vitro studies deciphering the role of EVs in
GBM51,52. Yet, additional work is needed to validate our current
conclusions in an in vivo setting, considering the role of the
surrounding microenvironment. Furthermore, as presented by
Rennert et al. RNA that is detectable in GBM EVs is a rather
appealing source of biomarkers as only a small amount of genetic
material is needed to perform the analysis of a few key genes.
Similarly to the present study, authors suggested that describing
EV content expression patterns of the four different GBM sub-
types is urgently needed26. Also, larger vesicles, such as m/lEVs
and oncosomes, might also provide meaningful information for
GBM diagnosis and prognosis21. Finally, future translational
clinical research should be performed in order to assess the
application of such observations into a liquid biopsy setup53.
In summary, our study improves the understanding of the
correlation between distinct GBM subtypes and associated
potential aggressiveness with respective EV production and
content. In addition, our ﬁndings suggest the existence of EV-
associated biomarker patterns for GBM subtype identiﬁcation in
patients. Consequently, we believe that further clinical work and
validation would bring new insight towards the development of
more effective therapeutic strategies and personalized treatments.
Methods
Cells and reagents. LN18, LN229, and U118 GBM cells (ATCC) were maintained
in Dulbecco’s modiﬁed Eagle medium (DMEM, Sigma-Aldrich) and T98, U87, and
U138 GBM cells (ATCC) were maintained in minimum essential medium (MEM,
Sigma-Aldrich). Astrocytes (Human Astrocytes, Sciencell) were maintained in
Astrocyte growth medium (ASGM, Cell Applications). Poly-L-lysine (Sigma-
Aldrich) at 2 µg cm−2 was used to coat every plastic vessel needed for astrocyte
culture. Cell line culture medium was supplemented with 100 Units mL−1 peni-
cillin, 100 µg mL−1 streptomycin, 2 mM L-glutamine (PSG, Sigma-Aldrich) and
10% heat inactivated fetal bovine serum (FBS, First Link).
G166 and GS090 (GBM patient-derived stem cells) were a kind gift from
Dr. Angela Bentivegna, University of Milan-Bicocca and Dr. David Nathanson,
University of California, Los Angeles, respectively. GBM stem cells were isolated
from GBM tumor samples following local Ethical Board approval54,55. GBM stem
cells were maintained as neurospheres in (DMEM/F-12, Sigma-Aldrich) completed
with B-27 without Vitamin A (Life Technologies), Hu EGF (20 µgmL−1), Hu FGF-b
(8 µg mL−1), Heparin (2 mgmL−1), 100 Units mL−1 penicillin, 100 µg mL−1
streptomycin, and Glutamax (Invitrogen). Cells were incubated at 37 °C in a
humidiﬁed atmosphere at 5% CO2. Medium was changed twice a week. GBM cells
(cell lines) and astrocytes were detached at conﬂuence using trypsin/EDTA. GBM
stem cells were disassociated using TrypleE Express Enzyme (Gibco) and separated
into single cells through a 70 µm cell strainer. The International Cell Line
Authentication Committee identiﬁes U118 as a derivative of U138 as they appeared
to share a common donor56,57. Nevertheless, considering the GBM intra-tumoral
heterogeneity, we decided to use both cell lines in the present study to compare
them with each other and with the rest of the cells we used5. All the cells were
tested negative for mycoplasma at the beginning of the study.
Cell invasion assay in HA hydrogels. Cells were incubated with HA hydrogels for
7 days according to the manufacturer’s instructions (Biomymesis, Celenys)58.
100,000 cells were seeded per well. All the steps conferring properties to HA
hydrogels used in cell culture have been described in two Europeans patents:
“Improved Crosslinked Hyaluronan Hydrogels for 3D Cell Culture” EP10305666.9,
June 22, 2010 and “Method for Harvesting Cells Cultured in 3D Hydrogel
Matrices” EP 10305667.7, June 22, 2010. Hyaluronan hydrogels consist of hya-
luronan cross-linked with adipic dihydrazide (ADH; Sigma-Aldrich, France) and
1-ethyl-3 [3-(dimethylamino)-propyl] carbodiimide (EDCI; Sigma-Aldrich). High
molecular weight hyaluronan (>106 Da; Sigma-Aldrich) is used to prepare the
hydrogel plates, as originally described by Prestwich et al.59. Brieﬂy, the ratios
ADH:hyaluronan (10:1) and hyaluronan:EDCI (1:1) have been optimized for cell
adhesion and culture. Hyaluronan and ADH are dissolved in milliQ-water. 0.1 N
HCl is used to adjust the pH to 4.6. The reaction mixture is then completed with
carbodiimide reagent (EDCI) and allowed to set for 2 h, with gentle agitation.
Hyaluronan hydrogels are then dialyzed against 0.1 N NaCl for 2 days, then in a
water:ethanol mixture (3:1 v/v) for other 2 days, and in milliQwater for 2 days in
order to remove excess of ADH and EDCI. In the next step, the dialyzed hydrogel
is placed in a plastic container and frozen. Following freezing, the hydrogels are
placed in a lyophilizer (Alpha 1–2, Christ, Germany; performances, 2 kg ice per 24 h,
T=−55 °C) for 4–5 days. The lyophilized hydrogels are then stored at −20 °C.
Hydrogels are sterilized at 100 °C. The gel pH post-rehydration has been shown to
be ~8.4. The swelling ratio of hyaluronan hydrogels at room temperature in culture
medium should be 37 g g−1 60. Colony counting was performed on six pictures
randomly taken from each gel using an EVOS FLC imaging system (Life Tech-
nologies) at ×10 magniﬁcation. Cell viability was assessed using the CellTiter-Glo®
Luminescent Cell Viability Assay. To do so, 100 µL of Cell-Titer-Glo® Reagent
(CellTiter-Glo® Luminescent Cell Viability Assay, Promega) was added to each
well. Plate was agitated on a plate mixer for 2 min and left for 10 min at room
temperature before luminescence was recorded using a GloMax Explorer plate
reader (Promega). Graphs show an average of three experiments.
Cell invasion assay through a basement membrane matrix. The QCM™ 96-well
plate (Merck) was used to perform the cell invasion assay. The assay allows for
measurement of cell invasion through a reconstituted basement membrane matrix.
Cells were starved in serum-free medium for 24 h before the assay, according to the
manufacturer’s instruction. The basement membrane matrix was rehydrated with
warm cell culture medium for 2 h. Medium was discarded from the inserts and
either serum-free medium (control) or 10% FCS medium was added to the feeder
tray (lower chamber). 100,000 cells per well were then seeded and allowed to
invade the matrix for 24 h. Following incubation, the cell suspension was carefully
removed from the top chamber and inserts were rinsed in sterile PBS for 1 min.
Cell detachment solution was then added to a new feeder tray and the plate was
incubated for 30 min so invading cells are dissociated from underside. In order to
label the cells, CyQuant GR Dye/4x Lysis Buffer solution was then added to the
wells. The plate was incubated for an additional 15 min at room temperature.
Finally, ﬂuorescence was read using a GloMax Explorer plate reader (480/520 nm
ﬁlter set, Promega). Data obtained in presence of FCS was normalized to data
obtained without FCS. Graph shows an average of three experiments.
Cell proliferation assay. Cells were plated in a 96-well plate (5000 cells per well)
in 10% FCS medium. Cells were incubated for 24 and 96 h, washed once with
sterile PBS and then ﬁxed using 4% paraformaldehyde for 20 min. Following, cells
were washed with PBS again and stained using a 0.1% crystal violet solution for
30 min. Crystal violet dye was then extracted from the cells using 10% acetic acid.
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Plates were placed on a plate shaker for 30 min. Absorbance was then read at
590 nm for both t24 and t96 time points using a GloMax Explorer plate reader
(Promega). Doubling time (h) was calculated using this formula: doubling time=
72/(log(absorbance590nm at t96) – log(absorbance590nm at t24))/log2). Graph shows
an average of three experiments.
Wound healing assay. Cells were plated at 100,000 cells per well in a 24-well plate
in 10% FCS medium until they reach 80% of conﬂuence. Then, cells were washed
once with sterile PBS and medium was changed for 0% FCS medium before a
scratch was performed in the cell layer using a 200 µL tip. Cells were incubated for
48 h. A total of three pictures per wound were taken using an EVOS FLC imaging
system (Life Technologies) at ×10 magniﬁcation. The size of the wound was then
measured on each picture. Graphs show an average of three experiments. The
wound healing assay could not be performed using G166 or GS090, as previously
reported61.
Western blotting. Cell protein lysates were extracted using RIPA buffer (Sigma)
including fresh protease and phosphatase inhibitors and standard western blotting
protocol was performed as described before62. For the EV marker analysis, 1 × 1011
sEVs mL−1 was loaded on the SDS gel. Primary antibodies: Anti-AnnexinA2
(Genscript A01471, 1/1000 dilution), anti-β-Actin (Abcam ab6276, 1/5000 dilu-
tion), anti-CD-9 (System Biosciences EXOAB-CD9A-1, 1/10000 dilution), anti-
CD44 (Cell Signaling #3570, 1/1000 dilution), anti-CD63 (System Biosciences
EXOAB-CD63A-1, 1/10,000 dilution), anti-CD81 (System Biosciences EXOAB-
CD81A-1, 1/10,000 dilution), anti-Fibronectin (Abcam ab2413, 1/1000 dilution),
anti-HSP-70 (System Bisociences EXOAB-HSP70A-1,1/10,000 dilution), anti-
NEFL (Cell Signaling #2837, 1/1000 dilution), anti-OLIG2 (Genscript A01474,
1/1000 dilution), and anti-PTEN (Cell Signaling #9188, 1/1000 dilution). Sec-
ondary antibodies used: Polyclonal Goat Anti-Rabbit/Mouse Immunoglobulins/
HRP (Dako P0447/8, 1/3000 dilution) antibodies and Anti-Rabbit Immunoglo-
bulins/HRP (ExoAb antibody Kit, System Biosciences EXO-AB-HRP, 1/3000
dilution). Chemiluminescence was observed using a UVP Chemstudio instrument
(Analytik Jena) and the Vision Works software. All experiments have been repe-
ated at least three times.
Real-time polymerase chain reaction. RNA was puriﬁed from cell pellets using
the RNeasy® mini kit (Qiagen) quick start protocol. Reverse transcription was
carried out using a cDNA synthesis kit (Applied Biosystems). Taqman (Applied
Biosystems) and cDNA were mixed with primers (Applied Biosystems) speciﬁc for
the markers of interest and run on a One-Step® Plus machine (Applied Biosys-
tems). Data was evaluated using One-Step® Plus software (Applied Biosystems).
Each result has been normalized to GAPDH values. Graphs show an average of at
least three experiments. All the primers (Table 1) were obtained from Applied
Biosystems (Thermoﬁsher), except primers for PDGF-Rα and GAPDH (Qiagen).
VEGF-A ELISA. Human VEGF DUOSET ELISA (R&D System) was used to
measure VEGF-A levels in culture medium according to the manufacturer’s
instructions. Absorbance was measured at 450 nm using a GloMax Explorer plate
reader (Promega). Graphs show an average of three experiments.
Extracellular vesicle concentration. In order to collect sEVs derived from GBM
cell lines (LN18, U87, and U118), cells were seeded in 4–5 × 175 cm2 ﬂasks and
grown in 10% FCS medium until they reach conﬂuence. Then, cells were washed
with sterile PBS and 15 mL of corresponding serum-free medium was added to
each ﬂask for 24 h. Following this incubation, conditioned medium (CM) was
collected and kept at either 4 °C for a very short time (up to 24 h) or at −20 °C for
longer periods (up to 6 months) before sEV concentration.
To collect sEVs from GBM stem cells (G166 and GS090) in suspension cell
culture (neurospheres), medium was changed at conﬂuence (neurospheres of
150–200 µm diameter) and incubated for 24 h before CM collection. To do so,
culture supernatant and neurospheres were centrifuged at 400 × g for 4 min and
CM was collected (35 mL). CM from GBM stem cell cultures was then kept at
either 4 °C for a very short time (up to 24 h) or at −20 °C for longer periods (up to
6 months) before sEV concentration. In accordance with the latest minimal
information for studies of EVs, cell count at time of collection was recorded and
used to normalize the ﬁnal sEV concentration (particles/mL/cell)21.
Concentration of sEVs was performed using an ultracentrifugation-based
protocol63. Every step of the concentration protocol was performed at 4 °C. An
initial 300 × g centrifugation was performed for 10 min to discard any ﬂoating cells
from the CM, followed by a 10 min centrifugation step at 2000 × g to remove any
ﬂoating cell debris and dead cells (Hettich Universal 320R centrifuge). A 10,000 × g
ultracentrifugation step (Beckman optima LE 80-k ultracentrifuge, Beckman Type
70 Ti rotor, Beckman polypropylene centrifuge 14 × 89 mm tubes, full dynamic
braking, kadj= 15,638) was then performed for 30 min to remove any further cell
debris and large vesicles (m/lEVs) from the CM. Finally, a ﬁrst 100,000 × g
ultracentrifugation run was performed for 1 h30 min to pellet the sEVs
(‘exosomes’) from the CM (Beckman optima LE 80-k ultracentrifuge, Beckman
Type 70 Ti rotor, Beckman polypropylene centrifuge 14 × 89 mm tubes, full
dynamic braking, kadj= 494). Supernatant was stored at −20 °C. The sEV pellet
was then washed in ﬁltered sterile PBS and centrifuged again for 1 h30 min at
100,000 × g in order to discard contaminants. The ﬁnal sEV pellet was re-
suspended in 100 µL ﬁltered sterile PBS and immediately characterized through
nanoparticle tracking analysis (NTA).
Further characterization of the sEVs was performed through western blotting
(see subsection ‘Western blotting’ in “Methods” section) by measuring the
expression of EV membrane associated markers, such as CD63, CD9, CD81
(mainly associated with light sEVs) and ﬁbronectin (mainly associated with dense
sEVs), and EV cytosolic markers such as HSP70 and Annexin A217,21.
Nanoparticles tracking analysis (NTA). Vesicle concentration and size were
determined using a Nanosight© NS300 and the Nanosight© NTA 3.2 software
(Malvern Instruments). The following conditions were applied for the NTA ana-
lysis at the Nanosight instrument: temperature was 20–25 °C; viscosity was ~0.98
cP; camera type was sCMOS; laser type was Blue488; camera levels were either 14
or 15; syringe Pump Speed was set to 70 AU; ﬁve measurements of 60 s each were
recorded. Graphs show an average of at least four experiments.
Transmission electron microscopy. Transmission electron microscopy (TEM)
has been performed on sEV preparations in order to visualize and assess/conﬁrm
the size range of the vesicles, as described before63. Samples were visualized using a
JEOL JEM1400-Plus (120 kV, LaB6) microscope equipped with a Gatan OneView
4K camera at ×20k magniﬁcation. 10–15 pictures per grid were taken.
Mass spectrometry. In order to elucidate the protein content of the GBM cell-
derived sEVs, MS analysis was performed. To do so, a Bradford assay was per-
formed to determine the protein concentration of each sEV sample and 100 ng was
then loaded on a SDS–PAGE gel for protein separation. Following Coomassie blue
staining, 5 slices/lane were then cut out of the gel and further processed for in-gel
trypsin digestion and MS run. De-staining was performed through 3 changes/
washes with 50% acetonitrile (MeCN), 25 mM NH4HCO3, with 5 min shaking
between each change. Reduction and alkylation were performed, respectively, with
10 mM dithiothreitol (DTT), in 25 mM NH4HCO3 (45 min at 50 °C) and 50 mM
chloracetamide, 25 mM NH4HCO3 (45 min in the dark at room temperature).
Subsequently, 12.5 ng µL−1 trypsin (in 25 mM NH4HCO3) was added to the
samples, followed by an overnight incubation at 37 °C. The digest solution was then
transferred to clean tubes. Next, 70% acetonitrile/5% triﬂuoroacetic acid was added
to the gel pieces. Following 5 min shaking, the supernatant was transferred to the
corresponding clean tubes. A similar further extraction was repeated another two
times in order to completely dehydrate the gel pieces and consequently recover the
rest of the peptides. Sample volume was reduced to 20 µL using a vacuum con-
centrator. Samples were then processed through a LTQ-Orbitrap mass spectro-
meter coupled to a Dionex NCP-3200 nanoLC system. The raw data was searched
using Maxquant (Max Planck Institute of Biochemistry) against a SwissProt
database (Proteome ID: UP000005640, Taxonomy: 9606—Homo sapiens). The
following settings were used: trypsin was the enzyme with up to two missed
cleavages, oxidation (M) and acetyl (Protein N-term) were set as variable mod-
iﬁcations, Carbamidomethyl (C) was set as ﬁxed modiﬁcation, minimum peptide
length was seven amino acids, maximum peptide mass was 4600 Da, minimum and
maximum peptide length for unspeciﬁc search was 8 and 25 amino acids,
respectively, peptides and protein false discovery rates (FDR) were both 0.01 and
minimum razor+ unique peptides was set to 1 (minimum of 1 peptide for protein
identiﬁcation). Finally, results (‘protein groups’) were exported to Microsoft Ofﬁce
Excel and further processed. The MS analysis was repeated at least three times for
each GBM cell lines/stem lines, using independent samples. Through comparison
of independent experiments for each cell line/stem cell, we described as ‘hits’ the
identiﬁed proteins that appeared in at least two independent identiﬁcations.
Obvious contaminants (keratins) were removed from the protein group lists. In
addition, proteomic data were further deciphered by loading the gene symbols
identiﬁed from the MS data in Functional Enrichment Analysis Tool (FunRich) for
gene-enrichment analysis of ‘Biological pathways’, ‘Biological process’, ‘Cellular
Table 1 Primers used for RT-PCR assays
Gene Primer Source
EGF-R Hs01076090_m1 Applied Biosystems (Thermoﬁsher)
PTEN Hs02621230_s1 Applied Biosystems (Thermoﬁsher)
NF1 Hs01035108_m1 Applied Biosystems (Thermoﬁsher)
VEGF-A Hs00900055_m1 Applied Biosystems (Thermoﬁsher)
OLIG2 Hs00300164_s1 Applied Biosystems (Thermoﬁsher)
SOX2 Hs00415716 Applied Biosystems (Thermoﬁsher)
GAPDH Hs99999905_m1 Applied Biosystems (Thermoﬁsher)
PDGF-Rα Hs_PDGFRA_1_SG Qiagen
GAPDH Hs_GAPDH_2_SG Qiagen
ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-019-0560-x
10 COMMUNICATIONS BIOLOGY |           (2019) 2:315 | https://doi.org/10.1038/s42003-019-0560-x | www.nature.com/commsbio
component’ and ‘Pairwise comparison diagram’. The InteractiVenn (www.
interactivenn.net) online software was used to make Venn diagrams64.
TCGA data. Information about the distribution of speciﬁc gene hits among the
different GBM subtypes has been obtained from The Cancer Genome Atlas
(TCGA) through the ‘Expression box plot (Affymetrix HT HG U133A)’ and
‘Expression box plot (Affymetrix Human Exon 1.0 ST)’ graphs on the Betastasis
website (www.betastasis.com) that organize patients’ samples according to their
GBM subtypes.
Experimental design and statistics. Sample size was set to a minimum of three
independent experiments (biological repeats) based on the magnitude and con-
sistency of differences between cells/conditions. Experimental ﬁndings were reli-
ably reproduced. All the results were normalized to control and reported as mean
± standard error of the mean (SEM). Ordinary one-way ANOVA tests were
employed to determine the signiﬁcance of the observed differences. Tukey’s test
was used for multiple comparison. Differences were considered statistically sig-
niﬁcant at p < 0.05 (95% conﬁdence interval, *p < 0.05; **p < 0.01; ***p < 0.001).
Pearson correlation coefﬁcient was used to measure the relationship between the
considered parameters shown in Fig. 1. Mean phenotype parameter measurement
across all available cell lines was decomposed into seven different signatures (sig
1–7, Fig. 2a) to reduce the dimensionality of the data and provide a method of
clustering the cell lines by phenotype similarity. Additionally the LN18, U87, U118,
G166, and GS090 cell lines alone were decomposed into four signatures (sig 1–4,
Fig. 2c). This decomposition was achieved using non-negative matrix factorization
(NMF). Each cell-line’s mean parameter measurement was used to build a feature
matrix. NMF was used to decompose these features into two separate matrices, the
basis, which describes the composition of each signature and the coefﬁcient, which
reports how prominent each signature is in each cell line and stem cell. The
number of components parameter used for each decomposition was decided by
running many NMF decompositions with increasing parameters, and choosing the
number of components where the reconstruction error plateaued. Finally, we used
hierarchical clustering on the coefﬁcient matrices in order to cluster GBM cell lines
and stem cells based on signature composition similarity (Fig. 2b, d, respectively).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All relevant data are available from the authors upon request. The mass spectrometry
proteomics data have been deposited to the ProteomeXchange Consortium via the
PRIDE partner repository with the dataset identiﬁer PXD01457965.
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